Skip to main content

The efficacy of traditional Chinese medicine in the treatment of the COVID-19 pandemic in Henan Province: a retrospective study



Since 2020, novel coronavirus disease (COVID-19) has posed serious threats to health systems and led to tremendous economic decline worldwide. Traditional Chinese medicine (TCM) is considered a promising treatment strategy for COVID-19 in China and is increasingly recognized as a key participant in the battle against COVID-19. Clinicians also need accurate evidence regarding the effectiveness of TCM treatments for COVID-19.


We retrospectively analyzed patients diagnosed with COVID-19 by collected from the electronic medical records of the hospitals in Henan Province from January 19, 2020, to March 2, 2020. Demographic characteristics, clinical data, frequency analysis of Chinese patent medicines (CPMs), Chinese medicine injections (CMIs), evaluation of baseline symptom scores, nucleic acid negative conversion, length of hospitalization, and mortality rates were studied.


Between 15 January 2020 and 2 March 2020, 131 hospitals with 1245 patients were included. Survey response Chinese herbal decoction, CPMs, and CMIs combined with conventional Western medicine (CWM) used for the treatment of COVID-19. The top 8 CPMs were Lianhua Qingwen capsules, Shuanghuanglian oral liquid, Pudilan Xiaoyan oral liquid, Banlangen granules, Lanqin oral liquid, compound licorice tablets, Bailing capsules, montmorillonite powder. The most frequently used CMIs were Xuebijing, Tanreqing, Reduning, Xiyanping and Yanhuning. TCM combined with CWM improved the patients’ symptom scores for fever, cough, chest tightness, shortness of breath, and fatigue. Nucleic acid negative conversion occurred at11.55 ± 5.91 d and the average length of hospitalization was 14.92 ± 6.15 d. The mortality rate was approximately 1.76%, which is a reduction in patient mortality.


TCM combined with CWM improved clinical symptoms and reduced hospitalization and mortality rates.


COVID-19 has remarkably weakened the global economy by threatening health systems worldwide. Recently, there have been 643,875,406 confirmed cases of COVID-19, including 6,630,082 deaths, a total of 12,998,974,878 vaccine doses have been administered, all over 200 countries and territories (WHO,, as of 4 December 2022), however, the long-term outcomes of the COVID-19 pandemic are still difficult to predict. Thus far, effective drugs to treat COVID-19 are lacking, hence, it is necessary to explore several potential antiviral drug strategies for COVID-19, especially complementary and integrative medicines.

Traditional Chinese medicine (TCM) is promising for the treatment and prevention of COVID-19, and it is expected that TCM will be promoted by countries worldwide [1]. Numerous studies have reported that combined therapy with TCM and conventional Western medicine (CWM) significantly reduced mortality and improved fever and cough symptoms compared to using CWM alone [2]. Studies have shown that using TCM to treat COVID-19 in mainland China has brought new hope to the fight against the pandemic and has also provided many potentially effective drugs for further optimization [3].

In this study, we extracted a series of interrelated data, including epidemiological information, TCM syndrome differentiation, clinical characteristics, as well as data on the effectiveness and safety of integrated TCM and CWM in COVID-19 patients in Henan Province. We aim to explore the association of utilizations of TCM in the treatment of COVID-19, and clinical outcomes included in-hospital mortality, length of hospitalization. We present evidence for the diagnosis and treatment of COVID-19, as well as a brief overview of the status of and issues with TCM in the treatment of this global pandemic.


Data source and study sample

In the retrospective study of patients who were hospitalized with laboratory-confirmed SARS-CoV-2 infections in 131 hospitals, which were involved in epidemic prevention and control between 15 January 2020 and 2 March 2020 in Henan Province. (The First Affiliated Hospital of Henan University of CM, The First Affiliated Hospital of Zhengzhou University, Henan Provincial People’s Hospital, The Sixth Peoples Hospital of Zhengzhou, Nanyang Central Hospital, Zhumadian Central Hospital, The First Affiliated Hospital of Henan University of Science and Technology, Fifth People's Hospital of Anyang, among others). Electronic medical records (EMRs) were extracted and a data form was used to collect patient characteristics, such as patients’ gender, age, Wuhan or Hubei travel history, comorbidities, treatment, and clinical outcomes.

In terms of data quality control, owing to the variety and dosage forms of TCM, the name of the drug is standardized and different dosage forms of the same drug are standardized as one. Two researchers independently verified the eligibility of the patients for this study and retrieved the data.

COVID-19 diagnosis and treatment protocol

Patients were treated in accordance with the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (5th version) published by the National Health Commission of China. The treatment strategies for COVID-19 include CWM combined with TCM, CWM including oxygen therapy, antibiotics, antiviral medications, nutritional support, and other conventional treatments. TCM is used in a variety of dosage forms, including Chinese herbal decoctions, Chinese patent medicines (CPMs), granules, pills, Chinese medicine injections (CMIs) and other interventions.

Outcome assessments

Demographic characteristics and clinical symptoms

Demographic characteristics of patients with COVID-19, including sex, age, marital status, travel history, and comorbidities. We also assessed the clinical symptoms, including body temperature, cough, shortness of breath, chest tightness in severe cases, and fatigue at baseline and at 4, 7, 10, and 14 d after treatment.

Nucleic acid negative conversion, length of hospitalization and mortality rate

The gold standard for the diagnosis of COVID-19 is by RT-PCR of nasal or throat swabs. The first positive test was set as the date of diagnosis, and the date of two consecutive negative PCR tests was used as the cutoff, to calculate the length of the hospital stay. Mortality during hospitalization was also extracted.

Statistical analysis

Descriptive statistics were assessed as frequency, composition ratio or percentage. Continuous variables were expressed as mean and standard deviation (SD). For statistical analysis was performed using the Kruskal Wallis, results was considered statistically significant if the p value < 0.05. Data were analyzed using Origin software (version 2022).


Population characteristics

A total of 1245 cases with confirmed COVID-19 infection were analyzed. Among the patients, 677 (54.3%) were male and 568 (45.6%) were female, of the patients 1015 were married (approximately 81%). Infections occurred in patients of all ages, including newborn infants and the elderly, with high incidences of the disease at 25–49 (662) and 50–64 years (356). A total of 559 (44.8%) patients had a history of travel or residence in Wuhan, and 54.2% (675/1245) had a history of travel or residence in Henan Provinces other than Wuhan or Hubei. Comorbidities were common, the most common comorbidities were hypertension (191), diabetes (88), stroke (23), coronary heart disease (58), chronic kidney disease (8), chronic obstructive pulmonary disease (7), Chronic liver disease (3), and other abnormalities (63). The demographic characteristics of the participants are presented in Fig. 1.

Fig. 1
figure 1

Demographic characteristics of COVID-19 in Henan Province

TCM syndrome characteristics

The clinical symptom data of the patients at different admission times (baseline), after 4, 7, 10 and 14 days of hospitalisation, were summarised. Symptom scores, particularly respiratory symptoms at each timepoint, were compared with baseline, including fever, cough, chest tightness, shortness of breath and fatigue. The symptom scores of the different nodes before and after treatment were used to assess the improvement of the patients' symptoms.

Chinese herbal decoction treatment for COVID-19

Chinese herbal decoctions with good efficacy against COVID-19, including active pharmaceutical ingredients, for different stages of COVID-19 treatment (quercetin, wogonin, beta-sitosterol, baicalein, Kaempferol, luteolin, etc.). Various Chinese herbal formulations, such as Jing Fang Bai Du San or Yinqiao powder, have been used in the mild stage, when cold‒damp constrain and damp‒heat accumulation in the lung. The main patterns in the middle stage were damp‒toxin constraint in the lung and cold‒damp obstructing the lung; therefore, medicines such as Huopo xialing decoction, Mahuang dingchuan decoction, Ganlu xiaodu Dan, and Huashi baidu Fang were used to eliminate dampness. Huoxiang zhengqi is a commonly used damp clearing prescription that has the efficacy of reliving superficies, dispersing dampness, and harmonizing stomach. Later in the recovery period, Shasen Maidong was used to revitalize Qi and Yin, and Si/Liu junzi decoctions were used to nourish Qi and strengthen the spleen. These herbal decoctions contain a variety of components, including flavonoids, alkaloids, terpenoids, and polyphenols, and can alleviating cytokine storms, regulate immune imbalances, and produce the potential effect of synergistic treatment for COVID-19 quickly and effectively (Table 1).

Table 1 Pharmacological effects of Chinese herbal decoction and ingredients against COVID-19

Chinese patent medicines for COVID-19

According to our findings, the applications of Chinese patent medicines (CPMs) fall into four categories: heat-clearing agents, dampness-removing agents, cough suppressants, and tonics. Lianhua Qingwen, Shuanghuanglian Oral Liquid, and Pudilan Xiaoyan oral liquid are examples of representative heat-clearing and detoxifying CPMs. Damp-removing agents include Huoxiang zhengqi soft capsules, which have a similar pharmacological effect to decoction. Cough medications include Feilike mixture, Suhuang Zhike capsules, and Xuanfei Zhike mixture. Tonics such as Bailing capsules and Diyushengbai improve immune function. When the use of CPMs at 5 timepoints was summarized, Lianhua Qingwen was the most frequently used at all timepoints. With the passage of time, the total frequency of treatment drugs is also gradually decreasing; interestingly, Bailing Capsules are being used more frequently, placing them second in the 14 day administration (Fig. 2).

Fig. 2
figure 2

Top 8 CPMs in the 5 timepoints used for COVID-19 (Frequency ≥ 8). The number of patients who utilize a particular Chinese medication at the designated time period is the definition of "frequency."

Chinese medicine injections

Chinese medicine injections (CMIs) have become more widespread in China because of their instantaneous effects, fewer side effects, and significant tonic function. Furthermore, CMIs have been suggested to be significantly effective not only in the digestive and cardiovascular systems, but also in the respiratory system. We found that from admission to 4, 7, and 10 d of hospitalization, the most frequently used CMIs were Xuebijing, Tanreqing, Reduning, Xiyanping and Yanhuning, Similarly, the total frequency of CMIs is gradually decreasing over time, which is consistent with the trend of CPMs use (Fig. 3).

Fig. 3
figure 3

Top 5 CMI in the 5 timepoints used for COVID-19 (Frequently ≥ 6)

Clinical efficacy assessment

COVID-19 predominantly presents as a respiratory infection, with clinical manifestations including fever, cough, chest tightness, shortness of breath in severe cases, and fatigue. Patient clinical symptom information was used to evaluate the curative effect. We compared the clinical signs scored and plotted them at four timepoints, as indicated. Fever, fatigue and cough symptom scores significantly lower at days 4, 7, 10, and 14 compared to baseline (p < 0.05), chest tightness scores were significantly lower than baseline at days 10 and 14 after treatment, shortness of breath was statistically significant only after 14 days of treatment (p < 0.05). With the treatment stage, some patients are discharged from the hospital, and the number of patients and symptom scores are gradually decreasing (Fig. 4).

Fig. 4
figure 4

Clinical symptom scores at different timepoints

Nucleic acid negative conversion, length of hospital stay, and mortality rate

There were 1245 patients with a complete nucleic acid negative conversion date, with an average nucleic acid negative conversion of 11.55 ± 5.91 days and their average hospital stay was 14.92 ± 6.15 days (Fig. 5a). In our study, there were 22 fatal cases before February 29, 2020, and their average age was 71.2 years. The mortality rate was 1.76% (22/1245). Among the fatalities, 17 cases had well-defined complex comorbidities, including hypertension, chronic obstructive pulmonary disease, diabetes, and severe obesity, which were the most common comorbidities in the non-survivors (Fig. 5b).

Fig. 5
figure 5

Nucleic acid negative conversion, length of hospital stay, and mortality rate


COVID-19 belongs to the “epidemic disease” category in TCM. COVID-19 is spread primarily via respiratory droplets during close face-to-face contact, which is caused by the “yi qi” feeling of the disease. COVID-19 patients in Henan Province are mainly 18–60 years, with greater prevalence among men than women. Most patients had normal symptoms, and those who were severely or critically ill patients had underlying diseases, including hypertension, coronary heart disease, and diabetes. The complexity of comorbidities affects disease progression and patient prognosis. In our study, we found that 45% of the reported cases had a history of residence or travel in Wuhan.

Most patients with COVID-19 present with respiratory symptoms, such as fever, cough, chest tightness, and fatigue. In addition, patients exhibit a wide range of clinical manifestations, from asymptomatic to symptomatic. Previous studies have noted that a small percentage of patients experience gastrointestinal symptoms, with the most common being vomiting, abdominal pain, and diarrhea. A strong relationship between COVID-19 and the gut microbiome has been reported in literature [4]. Based on the theory of syndrome differentiation and the holistic view of TCM, it can simultaneously treat respiratory and gastrointestinal symptoms in COVID-19 patients.

A classified analysis of the efficacy and advantages of TCM for the prevention and treatment of COVID-19 has been performed, and this study can be a valuable reference for the application of TCM. Several representative Chinese herbal medicine formulations, including Jing Fang Bai Du San, were used to treat prevalent epidemic pathogens in ancient China. Jing Fang Bai Du San was found to temporarily improve the clinical symptoms of patients, and network pharmacology analysis initially revealed that the targets of Jing Fang Bai Du San in the treatment of COVID-19 mainly included EGFR, PIK3CA, LCK, and MAPK1 [5].

CPMs have been invaluable in the treatment of COVID-19. One of the most important TCM principles in the treatment of COVID-19 is syndrome differentiation. CPMs have the advantages of convenience and speed, and they can be used dialectically in the treatment of COVID-19 at various stages of the disease. The top ten CPMs have antiviral, antibacterial, and anti-inflammatory properties, as well as the ability to regulate immune inflammatory responses, protect against organ damage, improve pulmonary function, and alleviate clinical symptoms. A study found that LHQW can prevent or delay the progression to severe COVID-19 and inhibit influenza-induced bacterial adhesion by inhibiting adhesion molecules and improving severe pneumonia [6, 7]. HXZQ not only alleviates intestinal damage, but it also has anti-inflammatory and immunomodulatory properties in COVID-19, inhibiting inflammatory factors and modulating immune responses [8]. A randomized controlled trial discovered that HXZQ dropping pills and LHQW granules combined with CWM may have clinical benefits for improving clinical symptoms of COVID-19 patients, lowering anti-infective drug utilization, and improving patient prognosis [9]. FLKM has been shown in animal studies to alleviate pathological lung tissue injury, reduce neutrophil infiltration in rats with LPS-induced pneumonia, and alleviate clinical symptoms and signs in patients with pneumonia [10]. PDL protects against LPS-induced respiratory inflammation in mice [11]. Upper respiratory symptoms, fever, and altered taste remained the most common presenting symptoms. Extrapulmonary complications are also common, including the gastrointestinal tract, which explains the frequent use of Huoxiangzhengqi and montmorillonite.

CMIs significantly reduce the clinical symptoms of patients and prevent COVID-19 complications. CMIs were first recommended by the Chinese Clinical Guidance of COVID-19 Pneumonia Diagnosis and Treatment (4th edition), which suggested the application of Xiyanping injection in medium-term clinical treatment [12]. The results revealed that Xuebijing, Tanreqing, Reduning, Xiyanping, and Yanhuning were the most frequently used CMIs for COVID-19. Studies have found that Xuebijing has significant curative effects on sepsis through anti-inflammatory, anticoagulatory, immunoregulatory, vascular endothelial protective, and anti-oxidative stress effects. Tanreqing injection combined with CWM can effectively shorten the fever reduction time of community-acquired pneumonia and the hospitalization time of patients [13]. In vivo experiments have shown that Tanreqing injection can notably inhibit the expression of TNF-α, IL-6, IL-8, and IL-17A at both the gene and protein levels [14]. Reduning injection has achieved a certain effect in the clinical treatment of acute bronchitis and upper respiratory tract infections [15]. A multicenter, prospective, open-label, and randomized controlled trial on Xiyanping injection found that it can remarkably shorten the period of coughing and improve the recovery of patients with mild to moderate COVID-19 [16].

A series of CPMs and CMIs have played a promising role in the treatment of COVID-19.The most obvious finding to emerge from the analysis was that the symptoms of cough, fever, chest tightness, shortness of breath, fatigue, and other symptoms of the patients were significantly improved after a series of treatments. The average length of hospital stay (LOS) of patients in this study period was 14.92 ± 6.15 d, and the median LOS in the hospital was 14 d, with a range of 2–46 days. This may because most cases in Henan Province are mild and with common symptoms. In addition, we found that the case fatality rate (CFR) of patients with COVID-19 was approximately 1.76%, which is close to 2%. One study on 172 patients with COVID-19 between January 2020 and February 2020 in Henan Province had a CFR of 2.3% [17]. These results are in accordance with personal data from COVID-19 cases detected outside mainland China, which had an average CFR of 3.6%. [18]. A systematic review and meta-analysis revealed that the CFR of COVID-19 was 10%, while in hospitalized patients, the CFR was 13.0%. Among ICU patients, the CFR was as high as 37% [19]. The reason for the consistently low fatality rate in Henan Province may be closely related to the effects of TCM, and there may also be significant associations with patient age, sex, comorbidities, and stage after infection. In our study, we found that TCM with CWM has unique advantages in improving clinical symptoms, improving cure rate, reducing hospital stay, delaying disease progression, and reducing mortality.


Despite these promising results, this study has some limitations. First, the progress of COVID-19 treatment was not analyzed and there was a lack of a randomized control group. Second, some of the electronic medical records were incomplete. In addition, the combined application of different dosages of Chinese herbs have many complex ingredients, and their mechanisms of action need to be explored further. Despite the persistent limitations of TCM in epidemiological investigations, this study provides supplementary data on the clinical course of COVID-19 when TCM was used. Further studies should focus on improving the safety and efficacy of Chinese medicines to treat this respiratory epidemic.


In conclusion, our presentation provides better options and more convincing evidence for the clinical treatment of COVID-19. TCM combined with CWM improved clinical symptoms and reduced hospitalization and mortality rates. TCM has been practiced for thousands of years to treat large-scale pandemic diseases, and we hope that TCM can considerably control this novel respiratory infectious disease.

Availability of data and materials

The data sets from this study are available from the first author upon request.



Case fatality rate


Chinese medicine injections


Coronavirus disease 2019


Chinese patent medicines


Conventional western medicine


Electronic medical records


Length of stay


Traditional Chinese medicine


  1. Zhao Z, Li Y, Zhou L, Zhou X, Xie B, Zhang W, Sun J. Prevention and treatment of COVID-19 using traditional chinese medicine: a review. Phytomedicine. 2021;85: 153308.

    Article  CAS  PubMed  Google Scholar 

  2. Yin B, Bi YM, Sun L, Huang JZ, Zhao J, Yao J, Li AX, Wang XZ, Fan GJ. Efficacy of integrated traditional chinese and western medicine for treating COVID-19: a systematic review and meta-analysis of RCTs. Front Public Health. 2021;8(9): 622707.

    Article  Google Scholar 

  3. An X, Zhang Y, Duan L, Jin D, Zhao S, Zhou R, Duan Y, Lian F, Tong X. The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19. Biomed Pharmacother. 2021;137: 111267.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Villapol S. Gastrointestinal symptoms associated with COVID-19: impact on the gut microbiome. Transl Res. 2020;226:57–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Li J, Zhang K, Bao J, Yang J, Wu C. Potential mechanism of action of Jing Fang Bai Du San in the treatment of COVID-19 using docking and network pharmacology. Int J Med Sci. 2022;19(2):213–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Du Q, Huang W, Zhao J, Zeng J, Zhang W, Huang X, Chen R, Jiang H, Xie Y, Wang Y, Zhong N, Wang X, Yang Z. Lianhuaqingwen capsule inhibits influenza-induced bacterial adhesion to respiratory epithelial cells through down-regulation of cell adhesion molecules. J Ethnopharmacol. 2021;15(280): 114128.

    Article  Google Scholar 

  7. Liu M, Gao Y, Yuan Y, Yang K, Shi S, Tian J, Zhang J. Efficacy and safety of herbal medicine (Lianhuaqingwen) for treating COVID-19: a systematic review and meta-analysis. Integr Med Res. 2021;10(1): 100644.

    Article  CAS  PubMed  Google Scholar 

  8. Tong T, Wu YQ, Ni WJ, Shen AZ, Liu S. The potential insights of traditional chinese medicine on treatment of COVID-19. Chin Med. 2020;24(15):51.

    Article  Google Scholar 

  9. Xiao M, Tian J, Zhou Y, Xu X, Min X, Lv Y, Peng M, Zhang Y, Yan D, Lang S, Zhang Q, Fan A, Ke J, Li X, Liu B, Jiang M, Liu Q, Zhu J, Yang L, Zhu Z, Zeng K, Li C, Zheng Y, Wu H, Lin J, Lian F, Li X, Tong X. Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial. Pharmacol Res. 2020;161: 105126.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Peng J, Chen X, Hou M, Yang K, Yang B, Wang P, Du Y, Yu Q, Ren J, Liu J. The TCM preparation feilike mixture for the treatment of pneumonia: network analysis, pharmacological assessment and silico simulation. Front Pharmacol. 2022;28(13): 794405.

    Article  Google Scholar 

  11. Feng L, Yang N, Li C, Tian G, Wang J, Dong ZB, Jia XB, Di LQ. Pudilan xiaoyan oral liquid alleviates LPS-induced respiratory injury through decreasing nitroxidative stress and blocking TLR4 activation along with NF-ΚB phosphorylation in mice. J Ethnopharmacol. 2018;25(214):292–300.

    Article  Google Scholar 

  12. Li Y, Xu H, Lang H, Li J, Bi L, Li Y, Dong L, Zhang L, Liang X, Zhu H. The efficacy and safety of Chinese traditional medicine injections on patients with coronavirus disease 2019: a protocol for systematic review and meta analysis. Medicine. 2020;99(31): e21024.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Huang X, Duan X, Zhu Y, Wang K, Wu J, Tian X. Comparative efficacy of Chinese herbal injections for the treatment of community-acquired pneumonia: a bayesian network meta-analysis of randomized controlled trials. Phytomedicine. 2019;63: 153009.

    Article  PubMed  Google Scholar 

  14. Liu W, Zhang X, Mao B, Jiang H. Systems pharmacology-based study of Tanreqing injection in airway mucus hypersecretion. J Ethnopharmacol. 2020;1(249): 112425.

    Article  Google Scholar 

  15. Cao C, Zhen Z, Kuang S, Xu T. Reduning injection combined with western medicine for pneumonia: a protocol for systematic review and meta-analysis. Medicine. 2020;99(43): e22757.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Zhang XY, Lv L, Zhou YL, Xie LD, Xu Q, Zou XF, Ding Y, Tian J, Fan JL, Fan HW, Yang YX, Ye XQ. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: a multicenter, prospective, open-label and randomized controlled trial. Phytother Res. 2021;35(8):4401–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Zhang Q, Wang Z, Lv Y, Zhao J, Dang Q, Xu D, Zhao D, Liu H, Wang Z, Zhao X, Xu Z, Zhang X. Clinical features and prognostic factors of patients with COVID-19 in Henan Province. China Hum Cell. 2021;34(2):419–35.

    Article  CAS  PubMed  Google Scholar 

  18. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, Cuomo-Dannenburg G, Thompson H, Walker PGT, Fu H, Dighe A, Griffin JT, Baguelin M, Bhatia S, Boonyasiri A, Cori A, Cucunubá Z, FitzJohn R, Gaythorpe K, Green W, Hamlet A, Hinsley W, Laydon D, Nedjati-Gilani G, Riley S, van Elsland S, Volz E, Wang H, Wang Y, Xi X, Donnelly CA, Ghani AC, Ferguson NM. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Alimohamadi Y, Tola HH, Abbasi-Ghahramanloo A, Janani M, Sepandi M. Case fatality rate of COVID-19: a systematic review and meta-analysis. J Prev Med Hyg. 2021;62(2):E311–20.

    PubMed  PubMed Central  Google Scholar 

Download references


The authors thank all the doctors who are protecting people’s health and fighting against COVID-19. We are also thankful for the efforts of the Henan Provincial Administration of Traditional Chinese Medicine.


The financial support for the research was provided by the Natural Science Foundation of Henan Province of China (No. 14402014-2022), Henan Province Traditional Chinese Medicine Scientific Research Special Project (No. 2021JDZY102), Henan Province Epidemic Prevention and Control Scientific Research Project (No. 211100310500), State Administration of Traditional Chinese Medicine COVID-19 of TCM Emergency Special project (No.2021ZYLCYJ06-2, No.2022ZYLCYJ01-1), and Henan Province COVID-19 Traditional Chinese Medicine Scientific Research Special Project (No.2022ZYFY01). Doctoral Research Start-up Project of the First Affiliated Hospital of Henan University of Chinese Medicine (No. 2021BSJJ002).

Author information

Authors and Affiliations



RH, YX, HZ, BL, XY, MW, SYL, and JL contributed to this study. RH: visualization, original draft, writing, reviewing, and editing. YX: project administration and investigation. HZ: investigation. BL: investigation. XY: supervision. MW: supervision. SYL: project administration, resources, supervision. JL: project administration, resources, supervision. All authors agree to be accountable for all aspects of the work, ensuring its integrity and accuracy. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Suyun Li or Jiansheng Li.

Ethics declarations

Ethical approval and consent to participate

The study was designed and conducted in accordance with the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of The First Affiliated Hospital of Henan University of Chinese Medicine (Agreement Number: 2022-HL-026; Trial Registration Number: ChiCTR2100050139). Due to this study was retrospective study design, it also considered as posing minimal risk to the study participants.

Consent for publication

Not Applicable.

Competing interests

The authors declare they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Han, R., Xie, Y., Zhao, H. et al. The efficacy of traditional Chinese medicine in the treatment of the COVID-19 pandemic in Henan Province: a retrospective study. Eur J Med Res 28, 78 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • COVID-19
  • Chinese patent medicines
  • Chinese medicine injections
  • Long of stay
  • Traditional Chinese medicine